CMAAO Coronavirus Facts and Myth Buster - Favipiravir now in India |
Editorial
eMediNexus Coverage from: 
CMAAO Coronavirus Facts and Myth Buster - Favipiravir now in India

8 Read Comments                

With inputs from Dr Monica Vasudev954:  Favipiravir updateCurrently under investigation for use in the treatment of coronavirus disease 2019 (COVID-19)Safety and efficacy have not yet been established.COVID-19 (off-label use): Oral: Optimal dose and duration are unknown with only limited data available; 1,600 mg twice daily on day 1, followed by 600 mg twice daily for 7 to 14 days.Another clinical trial is using a dose of 2.4 g every 8 hours for 2 doses, followed by 1.2 g 8 hours ...
To read the complete article ,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now